MedTrace Logo

A Pharmacist-run PrEP Program for Women

NCT05755204 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 2

Last updated 2025-02-14

No results posted yet for this study

Summary

The primary objective of this study is to evaluate uptake and retention of long acting cabotegravir (LA-CAB) also known as Apretude versus daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) also known as Truvada for PrEP among high-risk women in metro-Orlando through week 48 (to also include reasons for lack of retention in PrEP care)

Conditions

  • HIV Prevention

Interventions

DRUG

LA-CAB

Intramuscular LA-CAB for PrEP

DRUG

TDF/FTC

Oral TDF/FTC for PrEP

Sponsors & Collaborators

  • Orlando Immunology Center

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-06-21
Primary Completion
2024-10-15
Completion
2024-10-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05755204 on ClinicalTrials.gov